Home>Topics>Stocks>Impax Laboratories

Impax Laboratories IPXL

  1. All
  2. Commentary
  3. Fund Reports
  4. Headlines
    1. Impax Labs get subpoena in price fixing probe

      Headlines

      Tue, 15 Jul 2014

      July 15 (Reuters) - - Impax Laboratories said it was subpoenaed by the Connecticut Attorney General regarding an investigating into possible price fixing of its generic heart drug, digoxin.

    2. Wall Street Breakfast: Brent Soars, GE Seals Deal, Oracle Acquisition

      Headlines

      Mon, 23 Jun 2014

      Wall Street Breakfast Editors submit: Economy With increasing Iraqi violence , Brent crude rose 62 cents to $115.43 by 6:35 a.m. GMT, and may break its Thursday record of $115.71 - the highest price since September 9. Militants yesterday took control of three towns, two crossings on the Iraq-Syrian

    3. Impax shares fall after FDA denies approval to Parkinson's drug

      Headlines

      Tue, 22 Jan 2013

      (Reuters) - Shares of Impax Laboratories Inc fell as much as 10 percent on Tuesday, after U.S. health regulators denied approval to the company's Parkinson's drug and asked for a reinspection of its...

    4. Impax gets FDA warning letter, shares fall

      Headlines

      Mon, 6 Jun 2011

      (Reuters) - Impax Laboratories Inc said it received a warning letter from U.S. health regulators on deficient sampling and testing of drugs at its Hayward, California-based plant, sending the...

    5. Prospects Brighten for Medicis' Solodyn

      Commentary

      Fri, 8 Oct 2010

      competition until late 2011, thanks to several deals with Teva TEVA, Sandoz (a unit of Novartis NVS), Mylan MYL, and Impax IPXL . By paying the generic companies to delay competition, Medicis has lengthened the runway for Solodyn. The firm may have bought

    6. CMSCX Columbia Small Cap Growth I Z Fund Analysis, Report, Research, 5 Star Rating – Morningstar

      Fund Reports

      Wed, 23 Dec 2009

      stocks. Nearly one fourth of this fund's assets are in micro-cap stocks such as top-10 holdings TNS TNS, Impax Laboratories IPXL , and Omnicell OMCL, and its average market cap is less than $1 billion, as opposed to Mid Cap Growth's

    7. Dropping Coverage of Impax

      Commentary

      Mon, 3 Aug 2009

      We are no longer providing equity research on Impax Labs IPXL . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    8. Medicis under Review

      Commentary

      Wed, 18 Mar 2009

      and expect to make a significant cut to our fair value estimate. Medicis had previously reached an agreement with Impax Labs IPXL (the first to file for approval) to delay the launch of its Solodyn generic until late 2011, but that may not hold if other

    9. Medicis Ends Solodyn Patent Dispute

      Commentary

      Tue, 2 Dec 2008

      Monday that it has settled all outstanding patent disputes over its acne drug Solodyn with generic drug maker Impax Laboratories . Under the agreement, Medicis will pay Impax $40 million up front in return for Impax working in partnership

    10. Medicis' Solodyn in Trouble

      Commentary

      Wed, 23 Jan 2008

      Medicis Pharmaceuticals MRX announced Jan. 15 that it received a formal patent challenge from Impax Laboratories IPXL concerning its Solodyn acne drug. We expect Solodyn to generate sales of about $200 million in 2007, or 44% of Medicis' total

    « Prev123Next »
    Content Partners